RxDoctor Payments Data

Valerie Leitko

Medical · Sparks, NVNPI 1336318583

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 438 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 38 manufacturers reported payments, led by AbbVie at 24.6% of the total. Among medical clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,199in general payments, 2019–2025

Across 438 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Novo Nordisk$658
  • GSK$579
  • Pfizer$561
  • Amgen$411
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$8,199100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,199 in reported general payments places this provider in the 90th percentile of 250 medical providers in Nevada.

See all medical providers in Nevada

Medicare billing

Part B allowed, 2024
$41,564
Medicare patients
142
Services billed
666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide54$61,466
JardianceEmpagliflozin33$38,483
EliquisApixaban23$38,314
FarxigaDapagliflozin Propanediol25$37,584
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$20,769
XareltoRivaroxaban11$15,241
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$5,576
Atorvastatin Calcium299$4,156
Lidocaine13$3,454
Albuterol Sulfate HfaAlbuterol Sulfate92$2,845
PremarinEstrogens, Conjugated12$2,705
Losartan Potassium227$2,054
Advair DiskusFluticasone Propion/Salmeterol11$2,033
Rosuvastatin Calcium76$1,955
Novolog FlexpenInsulin Aspart11$1,954

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$658$61,46654 claims
PfizerEliquis, Premarin$561$41,01935 claims
Boehringer IngelheimJardiance$194$38,48333 claims
AstraZenecaFarxiga$1,037$37,58425 claims
GSKTrelegy Ellipta$579$20,76920 claims
Johnson & JohnsonXarelto$50$15,24111 claims
AbbVieSynthroid$2,017$1,27116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 250 medical providers in Nevada.

Other medical in Sparks

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →